Selective RET Kinase Inhibitors and Lung Cancer.

N Engl J Med

From the Cancer Research Institute, Queen's University, Kingston, ON, Canada.

Published: November 2023

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe2311295DOI Listing

Publication Analysis

Top Keywords

selective ret
4
ret kinase
4
kinase inhibitors
4
inhibitors lung
4
lung cancer
4
selective
1
kinase
1
inhibitors
1
lung
1
cancer
1

Similar Publications

Mushrooms are considered one of the safe and effective medications because they have great economic importance due to countless biological properties. Cordyceps militaris contains bioactive compounds with antioxidant, antimicrobial and anti-cancerous properties. This study was projected to analyze the potentials of biometabolites and to extract antimicrobial peptides and protein from the C.

View Article and Find Full Text PDF

Rearranged during transfection (RET) lung cancer - Update on targeted therapies.

Lung Cancer

January 2025

Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4059, Australia; Translational Research Institute, Woolloongabba, Queensland 4102, Australia. Electronic address:

The enhanced comprehension of the molecular pathways underpinning oncogenesis in non-small cell lung cancer (NSCLC) has led to the advancement of personalized treatment for individuals with actionable mutations using targeted therapies. The rearranged during transfection (RET) proto-oncogene, is critical in the embryonic development of various tissues, including renal, neural, and neuroendocrine tissue. RET fusions have been observed in approximately 1-2% of NSCLC cases.

View Article and Find Full Text PDF

Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.

Cancer Lett

January 2025

Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address:

Anorexia is a major cause of cancer cachexia and is induced by growth differentiation factor-15 (GDF15), which activates the rearranged during transfection (RET) protein tyrosine kinase in the hindbrain through GDF family receptor α-like (GFRAL), raising the possibility of targeting RET for cancer cachexia treatment. RET-altered cancer patients treated with RET-selective kinase inhibitors gain weight, however, it is unclear whether this results from tumor regression that improves the overall health of patients. Thus, the potential of using a RET inhibitor to address cancer cachexia remains unknown.

View Article and Find Full Text PDF

This study reports a 50-year-old patient presented with eczematous drug-eruption induced by selpercatinib after the treatment of non-small cell lung cancer (NSCLC). The patient has symmetric erythematous papules and plaques all over the body with dry, scaly skin accompanied by severe pruritus and visible scarring. After systemic treatment with glucocorticoids, the patient' skin lesions were reduced well.

View Article and Find Full Text PDF

Objective: This study was to develop a multi-parametric MRI radiomics model to predict preoperative Ki-67 status.

Materials And Methods: A total of 120 patients with pathologically confirmed breast cancer were retrospectively enrolled and randomly divided into a training set (n = 84) and a validation set (n = 36). Radiomic features were derived from both the intratumoral and peritumoral regions, extending 5 mm from the tumor boundary, using magnetic resonance imaging (MRI).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!